Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Next Previous
Trial Profile

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary)
  • Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 14 Nov 2023 Planned initiation date (estimated date of first participant enrollment) changed from 30 Oct 2023 to 26 Jul 2024.
  • 14 Nov 2023 Status changed from not yet recruiting to recruiting.
  • 31 Oct 2023 According to an Agendia media release, company is collaborating with National Cancer Institute (NCI), part of the National institutes of Health and SWOG Cancer Research Network, funded by NCI, for a new clinical trial that will test the effectiveness of neoadjuvant immunotherapy for high-risk HR+ breast cancer patients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top